{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:01:52Z","timestamp":1789628512236,"version":"build-2803163510"},"reference-count":62,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,21]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      The precise role of C-peptide remains a subject of ongoing research, particularly in the context of type 2 diabetes mellitus (T2DM), characterized by both insulin resistance (IR) and beta cell dysfunction. This study evaluates the association between C-peptide levels and IR, insulin secretion, and beta cell function independent of other risk factors in T2DM patients with and without complications. This cross-sectional study included 91 T2DM participants with or without diabetic complications. Clinical variables, routine biochemical tests, and serum C-peptide levels were measured after overnight fasting. The levels of biomarkers (fasting insulin, C-peptide, resistin, and tumor necrosis factor alpha [TNF\u03b1]) were measured using a Randox Evidence biochip analyzer. Homeostatic model assessment (HOMA) of IR and beta-cell function was calculated using the software HOMA 2 calculator. The C-peptide index was also computed using a widely accepted formula. The mean fasting insulin (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001), homeostatic model assessment of IR (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .001), homeostatic model assessment of beta cell function (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .002), C-peptide index (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001), and TNF\u03b1 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .022) were significantly increased with tertiles of C-peptide. Patients with diabetic retinopathy and nephropathy had significantly higher levels of C-peptide. C-peptide levels significantly increased with the number of complications (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .010). The C-peptide levels were significantly associated with fasting insulin (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .000), homeostatic model assessment of beta cell function (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .011), C-peptide index (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .000), homeostatic model assessment of IR (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .000), and resistin (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .018) after adjustment for confounding factors such as age, gender, diabetes duration, body mass index, systolic blood pressure, low-density lipoprotein cholesterol, HbA1c, TNF\u03b1, and antidiabetic drugs (metformin and sulfonylurea) in diabetic patients with complications. This study illustrated the clinical utility of C-peptide in microvascular complications such as diabetic nephropathy and diabetic retinopathy. Moreover, C-peptide can be used as an appropriate index for identifying IR in T2DM patients with complications.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050326","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T17:06:37Z","timestamp":1787331997000},"page":"e50326","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the relationship between C-peptide levels and insulin resistance in patients with and without diabetic complications"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4860-1262","authenticated-orcid":false,"given":"Khalid","family":"Siddiqui","sequence":"first","affiliation":[{"name":"Strategic Center for Diabetes Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia"},{"name":"Department of Biochemistry, College of Medicine, Kuwait University, Safat, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salini S.","family":"Joy","sequence":"additional","affiliation":[{"name":"Strategic Center for Diabetes Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaik Sarfaraz","family":"Nawaz","sequence":"additional","affiliation":[{"name":"Strategic Center for Diabetes Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teena P.","family":"George","sequence":"additional","affiliation":[{"name":"Strategic Center for Diabetes Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish Kumar","family":"David","sequence":"additional","affiliation":[{"name":"Strategic Center for Diabetes Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Mujammami","sequence":"additional","affiliation":[{"name":"Strategic Center for Diabetes Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia"},{"name":"University Diabetes Center, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia"},{"name":"Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4792-5188","authenticated-orcid":false,"given":"Assim A.","family":"Alfadda","sequence":"additional","affiliation":[{"name":"Strategic Center for Diabetes Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia"},{"name":"Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia"},{"name":"Obesity Research Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0583-3901","authenticated-orcid":false,"given":"Mohamed","family":"Rafiullah","sequence":"additional","affiliation":[{"name":"Strategic Center for Diabetes Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260917","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"R2-20260917","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/1753-0407.12224","article-title":"Epidemiology of abnormal glucose metabolism in a country facing its epidemic: SAUDI-DM study.","volume":"7","author":"Al-Rubeaan","year":"2015","journal-title":"J Diabetes"},{"key":"R3-20260917","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.2147\/DMSO.S275898","article-title":"Obesity, insulin resistance, and type 2 diabetes: associations and therapeutic implications.","volume":"13","author":"Wondmkun","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"R4-20260917","doi-asserted-by":"crossref","first-page":"1478294","DOI":"10.1155\/2017\/1478294","article-title":"Insulin resistance, type 1 and type 2 diabetes, and related complications 2017.","volume":"2017","author":"Ndisang","year":"2017","journal-title":"J Diabetes Res"},{"key":"R5-20260917","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1210\/jc.2018-00500","article-title":"Frequent monitoring of C-peptide levels in newly diagnosed type 1 subjects using dried blood spots collected at home.","volume":"103","author":"Willemsen","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"R6-20260917","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13613-017-0274-5","article-title":"The effect of insulin administration on C-peptide in critically ill patients with type 2 diabetes.","volume":"7","author":"Crisman","year":"2017","journal-title":"Ann Intensive Care"},{"key":"R7-20260917","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.diabres.2015.01.016","article-title":"C-peptide: new findings and therapeutic possibilities.","volume":"107","author":"Wahren","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"R8-20260917","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.2337\/dc16-0360","article-title":"Fall in C-peptide during first 4 years from diagnosis of type 1 diabetes: variable relation to age, HbA1c, and insulin dose.","volume":"39","author":"Hao","year":"2016","journal-title":"Diabetes Care"},{"key":"R9-20260917","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/EJE-12-0085","article-title":"C-peptide and the risk for incident complications and mortality in type 2 diabetic patients: a retrospective cohort study after a 14-year follow-up.","volume":"167","author":"Bo","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"R10-20260917","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13098-017-0208-2","article-title":"C-peptide is independent associated with diabetic peripheral neuropathy: a community-based study.","volume":"9","author":"Qiao","year":"2017","journal-title":"Diabetol Metab Syndr"},{"key":"R11-20260917","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1111\/dom.14785","article-title":"C-peptide determination in the diagnosis of type of diabetes and its management: a clinical perspective.","volume":"24","author":"Maddaloni","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"R12-20260917","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.3390\/jcm9093001","article-title":"Plasma C-peptide and risk of developing type 2 diabetes in the general population.","volume":"9","author":"Sokooti","year":"2020","journal-title":"J Clin Med"},{"key":"R13-20260917","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.diabet.2019.04.004","article-title":"Association of C-peptide with diabetic vascular complications in type 2 diabetes.","volume":"46","author":"Wang","year":"2020","journal-title":"Diabetes Metab"},{"key":"R14-20260917","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jdiacomp.2014.12.013","article-title":"Relationship between serum C-peptide level and diabetic retinopathy according to estimated glomerular filtration rate in patients with type 2 diabetes.","volume":"29","author":"Chung","year":"2015","journal-title":"J Diabetes Complications"},{"key":"R15-20260917","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00592-010-0249-6","article-title":"Association between serum C-peptide levels and chronic microvascular complications in Korean type 2 diabetic patients.","volume":"49","author":"Kim","year":"2012","journal-title":"Acta Diabetol"},{"key":"R16-20260917","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12933-022-01636-z","article-title":"The bidirectional association of C-peptide with cardiovascular risk in nondiabetic adults and patients with newly diagnosed type 2 diabetes mellitus: a retrospective cohort study.","volume":"21","author":"Yan","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"R17-20260917","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.2147\/DMSO.S426956","article-title":"The correlation between C-peptide and severity of peripheral atherosclerosis in type 2 diabetes mellitus.","volume":"16","author":"Wahab","year":"2023","journal-title":"Diabetes Metab Syndr Obes"},{"key":"R18-20260917","doi-asserted-by":"crossref","first-page":"8883736","DOI":"10.1155\/2020\/8883736","article-title":"The association of fasting C-peptide with corneal neuropathy in patients with type 2 diabetes.","volume":"2020","author":"Zuo","year":"2020","journal-title":"J Diabetes Res"},{"key":"R19-20260917","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12902-023-01300-x","article-title":"The average 30-minute post-prandial C-peptide predicted diabetic retinopathy progress: a retro-prospective study.","volume":"23","author":"Pan","year":"2023","journal-title":"BMC Endocr Disord"},{"key":"R20-20260917","first-page":"1113","article-title":"Relationship between C peptide and chronic complications in type-2 diabetes mellitus.","volume":"97","author":"Sari","year":"2005","journal-title":"J Natl Med Assoc"},{"key":"R21-20260917","first-page":"1783","article-title":"C-peptide levels: correlation with anthropometric measurements of obesity and components of metabolic syndrome.","volume":"6","author":"Gilsa","year":"2024","journal-title":"Int J Acad Med Pharm"},{"key":"R22-20260917","first-page":"e56810","article-title":"C-peptide level in patients with uncontrolled type 2 diabetes mellitus on oral anti-diabetic drugs.","volume":"16","author":"Arya","year":"2024","journal-title":"Cureus"},{"key":"R23-20260917","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"R24-20260917","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1038\/s41598-017-02421-9","article-title":"Assessment of the diagnostic value of different biomarkers in relation to various stages of diabetic nephropathy in type 2 diabetic patients.","volume":"7","author":"Al-Rubeaan","year":"2017","journal-title":"Sci Rep"},{"key":"R25-20260917","doi-asserted-by":"crossref","first-page":"51786","DOI":"10.18632\/oncotarget.15239","article-title":"OGTT 1h serum C-peptide to plasma glucose concentration ratio is more related to beta cell function and diabetes mellitus.","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"R28-20260917","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1210\/jcem.87.7.8638","article-title":"Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men.","volume":"87","author":"Sepp\u00e4l\u00e4-Lindroos","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R29-20260917","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.pcd.2019.03.009","article-title":"Association of non-alcoholic fatty liver disease with microvascular complications of type 2 diabetes.","volume":"13","author":"Afarideh","year":"2019","journal-title":"Prim Care Diabetes"},{"key":"R30-20260917","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3389\/fendo.2014.00204","article-title":"Obesity-induced inflammation and insulin resistance.","volume":"5","author":"Ota","year":"2014","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R31-20260917","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cvr\/cvu211","article-title":"C-peptide replacement therapy as an emerging strategy for preventing diabetic vasculopathy.","volume":"104","author":"Bhatt","year":"2014","journal-title":"Cardiovasc Res"},{"key":"R32-20260917","doi-asserted-by":"crossref","first-page":"858692","DOI":"10.1155\/2012\/858692","article-title":"C-peptide: a new mediator of atherosclerosis in diabetes.","volume":"2012","author":"Vasic","year":"2012","journal-title":"Mediators Inflamm"},{"key":"R33-20260917","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.2337\/diabetes.53.7.1664","article-title":"C-peptide induces chemotaxis of human CD4-positive cells: involvement of pertussis toxin-sensitive G-proteins and phosphoinositide 3-kinase.","volume":"53","author":"Walcher","year":"2004","journal-title":"Diabetes"},{"key":"R34-20260917","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1161\/01.RES.0000251785.83860.3b","article-title":"C-Peptide in insulin resistance and vascular complications: teaching an old dog new tricks.","volume":"99","author":"Bruemmer","year":"2006","journal-title":"Circ Res"},{"key":"R35-20260917","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2337\/db08-1611","article-title":"Functional assessment of pancreatic beta-cell area in humans.","volume":"58","author":"Meier","year":"2009","journal-title":"Diabetes"},{"key":"R36-20260917","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1507\/endocrj.K10E-399","article-title":"Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes.","volume":"58","author":"Saisho","year":"2011","journal-title":"Endocr J"},{"key":"R37-20260917","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1007\/s00125-012-2466-8","article-title":"Pancreatic diabetes manifests when beta cell area declines by approximately 65% in humans.","volume":"55","author":"Meier","year":"2012","journal-title":"Diabetologia"},{"key":"R38-20260917","first-page":"463","article-title":"Relationship between modified homeostasis model assessment\/correlative serum factors and diabetic retinopathy among type 2 diabetics with insulin therapy in Guangzhou, China.","volume":"7","author":"Hu","year":"2014","journal-title":"Int J Ophthalmol"},{"key":"R39-20260917","first-page":"115","article-title":"Level of fasting C-peptide as a predictor of \u03b2-cell function in sudanese patients with type 2 diabetes mellitus.","volume":"07","author":"Zaki","year":"2019","journal-title":"J Biosci Med"},{"key":"R40-20260917","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/j.1464-5491.2012.03655.x","article-title":"Disordered insulin secretion in the development of insulin resistance and Type 2 diabetes.","volume":"29","author":"Schofield","year":"2012","journal-title":"Diabet Med"},{"key":"R41-20260917","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2478\/jtim-2024-0014","article-title":"Chinese expert consensus on blood lipid management in patients with diabetes (2024 edition).","volume":"12","author":"Xiao","year":"2024","journal-title":"J Transl Int Med"},{"key":"R42-20260917","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/joim.12071","article-title":"Ectopic lipid storage and insulin resistance: a harmful relationship.","volume":"274","author":"Bor\u00e9n","year":"2013","journal-title":"J Intern Med"},{"key":"R43-20260917","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society.","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"R44-20260917","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s42000-025-00737-0","article-title":"Involvement of C-peptide in the progression of type 2 diabetes mellitus through triglyceride-centered lipid metabolism.","volume":"25","author":"Li","year":"2026","journal-title":"Hormones (Athens)"},{"key":"R45-20260917","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/jdi.13371","article-title":"Association between the triglyceride-glucose index and diabetic nephropathy in patients with type 2 diabetes: a cross-sectional study.","volume":"12","author":"Liu","year":"2021","journal-title":"J Diabetes Investig"},{"key":"R46-20260917","doi-asserted-by":"crossref","first-page":"1442230","DOI":"10.3389\/fendo.2025.1442230","article-title":"Association of triglyceride glucose index with diabetic retinopathy in middle-aged and elderly ambulatory type 2 diabetic patients.","volume":"16","author":"Yao","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R47-20260917","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.2147\/DMSO.S478287","article-title":"Role of triglyceride-glucose index in type 2 diabetes mellitus and its complications.","volume":"17","author":"Pan","year":"2024","journal-title":"Diabetes Metab Syndr Obes"},{"key":"R48-20260917","doi-asserted-by":"crossref","first-page":"199","DOI":"10.14744\/ijmb.2025.43925","article-title":"Assessment of relationship between triglyceride\/HDL-C ratio and incident type 2 diabetes mellitus risk.","volume":"8","author":"Katar","year":"2025","journal-title":"Int J Med Biochem"},{"key":"R49-20260917","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3390\/pathophysiology29030029","article-title":"TG\/HDL-C ratio is a risk factor associated with CKD: use in assessing the risk of progression of CKD.","volume":"29","author":"Nguyen","year":"2022","journal-title":"Pathophysiology"},{"key":"R50-20260917","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1476-5381.2011.01369.x","article-title":"Resistin: functional roles and therapeutic considerations for cardiovascular disease.","volume":"165","author":"Jamaluddin","year":"2012","journal-title":"Br J Pharmacol"},{"key":"R52-20260917","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s10753-021-01549-1","article-title":"Inflammatory biomarkers and components of metabolic syndrome in adolescents: a systematic review.","volume":"45","author":"de F Rocha","year":"2022","journal-title":"Inflammation"},{"key":"R53-20260917","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.2040-1124.2011.00126.x","article-title":"Analysis of factors influencing postprandial C-peptide levels in Japanese patients with type 2 diabetes: comparison with C-peptide levels after glucagon load.","volume":"2","author":"Funakoshi","year":"2011","journal-title":"J Diabetes Investig"},{"key":"R54-20260917","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1463-1326.2009.01121.x","article-title":"Pdx1 and other factors that regulate pancreatic beta-cell survival.","volume":"11","author":"Fujimoto","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"R55-20260917","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.lpm.2009.02.023","article-title":"C-peptide and chronic complications in patients with type-2 diabetes and the metabolic syndrome.","volume":"38","author":"Mavrakanas","year":"2009","journal-title":"Presse Med"},{"key":"R56-20260917","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2174\/187152711799219271","article-title":"C-peptide and its correlation to parameters of insulin resistance in the metabolic syndrome.","volume":"10","author":"Banu","year":"2011","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"R57-20260917","doi-asserted-by":"crossref","first-page":"e91174","DOI":"10.1371\/journal.pone.0091174","article-title":"Age at diagnosis and C-peptide level are associated with diabetic retinopathy in Chinese.","volume":"9","author":"Cai","year":"2014","journal-title":"PLoS One"},{"key":"R58-20260917","doi-asserted-by":"crossref","first-page":"635158","DOI":"10.1155\/2008\/635158","article-title":"Intracellular signalling by C\u2010peptide.","volume":"2008","author":"Hills","year":"2008","journal-title":"Exp Diabetes Res"},{"key":"R59-20260917","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4172\/2165-8048.1000245","article-title":"C-peptide as a marker for diabetic nephropathy.","volume":"07","author":"Masoom","year":"2017","journal-title":"Intern Med"},{"key":"R60-20260917","doi-asserted-by":"crossref","first-page":"708","DOI":"10.2337\/dc12-1211","article-title":"C-peptide levels are associated with mortality and cardiovascular mortality in patients undergoing angiography: the LURIC study.","volume":"36","author":"Marx","year":"2013","journal-title":"Diabetes Care"},{"key":"R61-20260917","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s13300-017-0265-4","article-title":"A practical review of C-peptide testing in diabetes.","volume":"8","author":"Leighton","year":"2017","journal-title":"Diabetes Ther"},{"key":"R62-20260917","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1159\/000289864","article-title":"C-peptide as a therapeutic tool in diabetic nephropathy.","volume":"31","author":"Hills","year":"2010","journal-title":"Am J Nephrol"},{"key":"R63-20260917","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1089\/met.2015.0067","article-title":"C-peptide is a sensitive indicator for the diagnosis of metabolic syndrome in subjects from Central Mexico.","volume":"14","author":"Gonzalez-Mejia","year":"2016","journal-title":"Metab Syndr Relat Disord"},{"key":"R64-20260917","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.sjbs.2018.05.027","article-title":"Biomarker potential of C-peptide for screening of insulin resistance in diabetic and non-diabetic individuals.","volume":"25","author":"Khan","year":"2018","journal-title":"Saudi J Biol Sci"},{"key":"R65-20260917","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3803\/EnM.2017.32.2.230","article-title":"Association of plasma ghrelin levels with insulin resistance in type 2 diabetes mellitus among Saudi subjects.","volume":"32","author":"Al Qarni","year":"2017","journal-title":"Endocrinol Metab (Seoul)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050326","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:02:17Z","timestamp":1789624937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":62,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050326","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"2025-01-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}